Twist Bioscience (NASDAQ:TWST) Sets New 12-Month High – Should You Buy?

Posted by Francis Steltz on Sep 25th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $170.66 and last traded at $164.60, with a volume of 2313734 shares traded. The stock had previously closed at $165.83.

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

Positive Sentiment: Twist’s partnership with Eli Lilly’s TuneLab AI-driven drug-discovery platform, under which Twist will serve as a preferred antibody-characterization data provider, strengthens its exposure to pharmaceutical research and artificial-intelligence applications. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
Positive Sentiment: The company’s latest quarterly results showed revenue of $118.4 million, up 23.2% year over year, while full-year revenue guidance was raised. Those results provide fundamental support for the recent rally, although Twist remains unprofitable and missed the latest quarterly EPS estimate.
Neutral Sentiment: TWST recently reached a new 12-month high, making the shares vulnerable to consolidation as investors lock in gains after the partnership-driven advance. Twist Bioscience Hits New 12-Month High
Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no measurable short-covering pressure. Because the figure conflicts with the article’s description of a “significant increase,” investors should treat the data cautiously.
Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at about $165.49. The filings state the sales were intended to cover tax withholding on vested equity awards, and each executive retained a substantial position, reducing—but not eliminating—the negative signal. SEC insider transaction filings
Negative Sentiment: Quiver data shows 87 insider sales and no purchases over the past six months. Combined with ongoing losses and a stock price well above many analyst targets, the pattern may weigh on momentum and valuation-sensitive investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Barclays lifted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. BWS Financial restated a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. Finally, Piper Sandler raised their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

Check Out Our Latest Stock Report on Twist Bioscience

Twist Bioscience Trading Up 16.1%

The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business has a 50-day simple moving average of $125.11 and a two-hundred day simple moving average of $86.46. The stock has a market cap of $11.54 billion, a price-to-earnings ratio of -82.90 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share. Equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at $10,402,335.08. The trade was a 2.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 348 shares of the company’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $165.49, for a total transaction of $57,590.52. Following the completion of the transaction, the insider owned 73,303 shares in the company, valued at approximately $12,130,913.47. This represents a 0.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 516,574 shares of company stock worth $77,493,635. Company insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TWST. QRG Capital Management Inc. bought a new stake in shares of Twist Bioscience during the second quarter worth approximately $277,000. Engineers Gate Manager LP acquired a new position in Twist Bioscience in the 2nd quarter valued at $3,333,000. Integrated Wealth Concepts LLC acquired a new position in Twist Bioscience in the 2nd quarter valued at $99,000. Allworth Financial LP increased its position in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after buying an additional 213 shares during the period. Finally, Nykredit A S bought a new position in Twist Bioscience during the 2nd quarter worth $283,000.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.